Carcinoma, Basal Cell Clinical Trial
Official title:
High-Intensity Focused Ultrasound (HIFU) for Treatment of Non-nodular and Recurrent Basal Cell Carcinomas of the Skin: Efficacy and Safety.
The overall objective of this study is to demonstrate the safety and efficacy of removal of Basal Cell Carcinoma (BCC) using a new investigational equipment based on high-intensity focused ultrasound. Basal cell carcinoma is the most common cancer in Europe, Australia and the U.S.A. The general upwards age shift in the population in these regions is expected to be accompanied by an increase in the incidence of this type of cancer. There are currently more the 20.000 BCC registrations in Denmark every year, and occurrences on a global scale are counted in several tens of millions per year. Finding new and more effective treatment methods are therefore highly relevant from both a clinical and socioeconomic perspective. The investigational device used in the investigation is a Danish developed system capable of making controlled and targeted thermo-mechanical treatment of small intradermal volumes containing e.g. BCC cells, but without inflicting damage to the surrounding tissue. The investigation involves an evaluation of the safety and efficacy profile 3 months after a single 3-5 minute treatment. Subsequent follow-up of secondary endpoints is done every third month until the end of the study one year after the treatment.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00875381 -
Analysis of Melanocytes (Pigment Cells) in Sun-Exposed Skin
|
N/A | |
| Recruiting |
NCT04362722 -
Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients
|
Phase 2 | |
| Completed |
NCT00218829 -
DMSO-PDT of BCC - A 6 Year Follow up
|
N/A | |
| Completed |
NCT02674009 -
Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC)
|
||
| Recruiting |
NCT05970497 -
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Terminated |
NCT02956889 -
To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT01204073 -
A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies
|
Phase 1 | |
| Completed |
NCT02029352 -
Topical Green Tea Ointment in Treatment of Superficial Skin Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT03569345 -
Basal Cell Carcinomas Treated With Ablative Fractional Laser and Ingenol Mebutate
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05463757 -
Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
|
||
| Completed |
NCT00189280 -
Aldara for the Treatment of Large and/or Multiple sBCC
|
Phase 3 | |
| Completed |
NCT03541252 -
Topical Laser-assisted Combination Chemotherapy for Basal Cell Carcinoma- a Clinical Study
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02367547 -
Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: HAL and BF-200 ALA Versus MAL
|
Phase 1/Phase 2 | |
| Completed |
NCT00007631 -
Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT05138328 -
Laser Treatment of Basal Cell Carcinoma Under Imaging Guidance
|
N/A | |
| Completed |
NCT03132636 -
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
|
Phase 2 | |
| Completed |
NCT00847912 -
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
|
Phase 4 | |
| Enrolling by invitation |
NCT02666833 -
Optical Imaging for Preoperative Delineation of Nonmelanoma Skin Cancers
|
N/A | |
| Completed |
NCT01482104 -
New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)
|
N/A | |
| Completed |
NCT01455363 -
Post-occlusive Reactive Hyperemia and Basal-cell Carcinoma
|
N/A |